Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Autolus Therapeutics (AUTL) EBT Margin (2017 - 2025)

Historic EBT Margin for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to 370.79%.

  • Autolus Therapeutics' EBT Margin changed N/A to 370.79% in Q3 2025 from the same period last year, while for Sep 2025 it was 430.66%, marking a year-over-year increase of 22444500.0%. This contributed to the annual value of 2165.36% for FY2024, which is 101080200.0% up from last year.
  • As of Q3 2025, Autolus Therapeutics' EBT Margin stood at 370.79%.
  • Autolus Therapeutics' EBT Margin's 5-year high stood at 203.03% during Q4 2022, with a 5-year trough of 16684745762.71% in Q3 2021.
  • Moreover, its 5-year median value for EBT Margin was 2443.96% (2023), whereas its average is 1390407584.67%.
  • In the last 5 years, Autolus Therapeutics' EBT Margin plummeted by 2000000000bps in 2021 and then soared by 2000000000bps in 2022.
  • Quarter analysis of 5 years shows Autolus Therapeutics' EBT Margin stood at 16684745762.71% in 2021, then surged by 100bps to 203.03% in 2022, then tumbled by -5465bps to 11298.03% in 2023, then crashed by -698bps to 90151.72% in 2024, then surged by 100bps to 370.79% in 2025.
  • Its last three reported values are 370.79% in Q3 2025, 227.12% for Q2 2025, and 756.36% during Q1 2025.